Drug and Health Product Submissions Under Review (SUR): Supplemental submissions under review
This list is current as of: 2026-03-31.
An Excel version of the updated SUR List is available from the Overview page.
| Medicinal Ingredient(s) | Therapeutic Area | Year, Month Submission was Accepted into Review | Company Name (available for submissions accepted into review on or after October 1, 2018) | Submission 'Class' (if applicable) (available for submissions accepted into review on or after October 1, 2018) |
|---|---|---|---|---|
| Acalabrutinib maleate | Antineoplastic agents | 2025-12 | AstraZeneca Canada Inc | Part of an 'aligned review' with a health technology assessment organization |
| Adalimumab | Immunosuppressants | 2024-09 | JAMP Pharma Corporation | Biosimilar |
| Aflibercept | Ophthalmologicals | 2025-12 | Bayer Inc | Not applicable |
| Alirocumab | Lipid modifying agents | 2024-12 | Sanofi-Aventis Canada Inc | Not applicable |
| Amivantamab | Antineoplastic agents | 2025-08 | Janssen Inc | Not applicable |
| Atezolizumab | Antineoplastic agents | 2025-09 | Hoffmann-la Roche Limited | Not applicable |
| Avapritinib | Antineoplastic agents | 2025-05 | Blueprint Medicines Corporation | Being reviewed under the Priority Review Policy Part of an 'aligned review' with a health technology assessment organization |
| Baricitinib | Immunosuppressants | 2026-03 | Eli Lilly Canada Inc | Not applicable |
| Belzutifan | Antineoplastic agents | 2025-12 | Merck Canada Inc | Not applicable |
| Belzutifan | Antineoplastic agents | 2026-03 | Merck Canada Inc | Not applicable |
| Benralizumab | Drugs for obstructive airway diseases | 2025-10 | AstraZeneca Canada Inc | Not applicable |
| Berotralstat hydrochloride | Other hematological agents | 2026-03 | Biocryst Pharmaceuticals Inc | Part of an 'aligned review' with a health technology assessment organization |
| Brexpiprazole | Psycholeptics | 2026-03 | Otsuka Pharmaceutical Co Ltd | Not applicable |
| Budesonide, formoterol fumarate dihydrate, glycopyrronium bromide | Drugs for obstructive airway diseases | 2025-10 | AstraZeneca Canada Inc | Not applicable |
| Cemiplimab | Antineoplastic agents | 2025-08 | Regeneron Canada Company | Not applicable |
| Coagulation factors II (human), IX (human), VII (human), X (human), proteins C, S | Antihemorrhagics | 2025-10 | Octapharma Pharmazeutika Produktionsges M B H | Not applicable |
| Corynebacterium diphtheriae CRM-197 protein, pneumococcal conjugate serotype 33F, pneumococcal polysaccharide serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, deOAc15B, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 35B | Vaccines | 2025-11 | Merck Canada Inc | Not applicable |
| Daratumumab | Antineoplastic agents | 2025-12 | Janssen Inc | Not applicable |
| Drospirenone, estetrol monohydrate | Sex hormones and modulators of the genital system | 2025-11 | Searchlight Pharma Inc | Not applicable |
| Dupilumab | Other dermatological preparations | 2025-11 | Sanofi-Aventis Canada Inc | Not applicable |
| Dupilumab | Other dermatological preparations | 2026-01 | Sanofi-Aventis Canada Inc | Not applicable |
| Dupilumab | Other dermatological preparations | 2026-02 | Sanofi-Aventis Canada Inc | Not applicable |
| Durvalumab | Antineoplastic agents | 2025-10 | AstraZeneca Canada Inc | Part of an 'aligned review' with a health technology assessment organization |
| Elinzanetant | Other gynecologicals | 2025-10 | Bayer Inc | Not applicable |
| Enfortumab vedotin | Antineoplastic agents | 2025-12 | Pfizer Canada ULC | Being reviewed under the Priority Review Policy Part of an 'aligned review' with a health technology assessment organization |
| Epcoritamab | Antineoplastic agents | 2026-03 | Abbvie Corporation | Being reviewed under the Priority Review Policy Part of an 'aligned review' with a health technology assessment organization |
| Fish oil, medium-chain triglycerides, olive oil, soybean oil | Blood substitutes and perfusion solutions | 2025-11 | Fresenius Kabi Canada Ltd | Not applicable |
| Guselkumab | Immunosuppressants | 2025-01 | Janssen Inc | Not applicable |
| Inebilizumab | Immunosuppressants | 2025-07 | Amgen Canada Inc | Not applicable |
| Iopromide | Contrast media | 2025-12 | Bayer Inc | Being reviewed under the Submissions Relying on Third-Party Data Guidance |
| Ipilimumab | Antineoplastic agents | 2025-11 | Bristol-Myers Squibb Canada | Not applicable |
| Iptacopan hydrochloride | Immunosuppressants | 2025-07 | Novartis Pharmaceuticals Canada Inc | Part of an 'aligned review' with a health technology assessment organization |
| Isatuximab | Antineoplastic agents | 2025-08 | Sanofi-Aventis Canada Inc | Part of an 'aligned review' with a health technology assessment organization |
| Larotrectinib sulfate | Antineoplastic agents | 2025-11 | Bayer Inc | Not applicable |
| Lisocabtagene maraleucel | Antineoplastic agents | 2026-03 | Bristol-Myers Squibb Canada | Not applicable |
| Lurbinectedin | Antineoplastic agents | 2025-08 | Jazz Pharmaceuticals Ireland Limited | Not applicable |
| Mepolizumab | Drugs for obstructive airway diseases | 2025-01 | GlaxoSmithKline Inc | Part of an 'aligned review' with a health technology assessment organization |
| Nivolumab | Antineoplastic agents | 2025-11 | Bristol-Myers Squibb Canada | Not applicable |
| Ocrelizumab | Immunosuppressants | 2026-01 | Hoffmann-la Roche Limited | Not applicable |
| Pegcetacoplan | Immunosuppressants | 2025-10 | Swedish Orphan Biovitrum AB (Publ) | Being reviewed under the Priority Review Policy Part of an 'aligned review' with a health technology assessment organization |
| Peginterferon alfa-2a | Immunostimulants | 2026-02 | Pharmaand GmbH | Not applicable |
| Pembrolizumab | Antineoplastic agents | 2025-11 | Merck Canada Inc | Being reviewed under the Priority Review Policy |
| Pembrolizumab | Antineoplastic agents | 2025-12 | Merck Canada Inc | Being reviewed under the Priority Review Policy Part of an 'aligned review' with a health technology assessment organization |
| Pembrolizumab | Antineoplastic agents | 2026-03 | Merck Canada Inc | Not applicable |
| Pirtobrutinib | Antineoplastic agents | 2026-01 | Eli Lilly Canada Inc | Not applicable |
| Pirtobrutinib | Antineoplastic agents | 2026-03 | Eli Lilly Canada Inc | Not applicable |
| Respiratory syncytial virus prefusion F protein (RSVPreF3) | Vaccines | 2026-01 | GlaxoSmithKline Inc | Not applicable |
| Retifanlimab | Antineoplastic agents | 2025-08 | Incyte Corporation | Part of an 'aligned review' with a health technology assessment organization |
| Risankizumab | Immunosuppressants | 2025-12 | Abbvie Corporation | Not applicable |
| Ritonavir | Antivirals for systemic use | 2026-01 | Abbvie Corporation | Not applicable |
| Roflumilast | Antipsoriatics | 2025-10 | Arcutis Canada, Inc. | Not applicable |
| Roflumilast | Antipsoriatics | 2026-02 | Arcutis Canada, Inc. | Not applicable |
| Sacituzumab govitecan | Antineoplastic agents | 2026-01 | Gilead Sciences Canada Inc | Part of an 'aligned review' with a health technology assessment organization |
| Sacituzumab govitecan | Antineoplastic agents | 2026-01 | Gilead Sciences Canada Inc | Part of an 'aligned review' with a health technology assessment organization |
| Selumetinib sulfate | Antineoplastic agents | 2025-09 | Alexion Pharma GmbH | Not applicable |
| Semaglutide | Drugs used in diabetes | 2025-04 | Novo Nordisk Canada Inc | Not applicable |
| Semaglutide | Drugs used in diabetes | 2026-01 | Novo Nordisk Canada Inc | Not applicable |
| Setmelanotide acetate | Antiobesity preparations, excluding diet products | 2026-03 | Rhythm Pharmaceuticals, Inc | Being reviewed under the Priority Review Policy Part of an 'aligned review' with a health technology assessment organization |
| Tafasitamab | Antineoplastic agents | 2025-06 | Incyte Corporation | Part of an 'aligned review' with a health technology assessment organization |
| Tapinarof | Antipsoriatics | 2025-10 | Organon Canada Inc. | Not applicable |
| Tarlatamab | Antineoplastic agents | 2025-09 | Amgen Canada Inc | Not applicable |
| Teclistamab | Antineoplastic agents | 2026-02 | Janssen inc | Being reviewed under the Priority Review Policy |
| Tirzepatide | Drugs used in diabetes | 2025-08 | Eli Lilly Canada Inc | Part of an 'aligned review' with a health technology assessment organization |
| Tirzepatide | Drugs used in diabetes | 2025-08 | Eli Lilly Canada Inc | Not applicable |
| Tirzepatide | Drugs used in diabetes | 2025-12 | Eli Lilly Canada Inc | Not applicable |
| Tirzepatide | Antineoplastic agents | 2026-02 | Eli Lilly Canada Inc | Not applicable |
| Trastuzumab deruxtecan | Antineoplastic agents | 2026-02 | AstraZeneca Canada Inc | Part of an 'aligned review' with a health technology assessment organization |
| Trastuzumab deruxtecan | Antineoplastic agents | 2026-03 | AstraZeneca Canada Inc | Being reviewed under the Priority Review Policy Part of an 'aligned review' with a health technology assessment organization |
| Trastuzumab deruxtecan | Antineoplastic agents | 2026-03 | AstraZeneca Canada Inc | Not applicable |
| Upadacitinib | Immunosuppressants | 2026-02 | Abbvie Corporation | Not applicable |
| Ustekinumab | Immunosuppressants | 2026-02 | Janssen Inc | Not applicable |
| Venetoclax | Antineoplastic agents | 2025-08 | Abbvie Corporation | Not applicable |